PeLeMed
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
OncologyInfectious Diseases
Technology Platform
AI‑augmented drug discovery platform that combines deep learning‑driven target identification, structure‑based design, and high‑throughput synthesis to generate highly selective small‑molecule candidates.
Opportunities
AI‑driven pipeline can rapidly generate novel candidates for high‑unmet‑need indications like FLT3‑resistant AML and functional cure of HBV, attracting strategic partnerships.
Risk Factors
Early‑stage programs carry high attrition risk; limited cash runway may require additional financing before IND‑enabling milestones.
Competitive Landscape
Competes with biotech firms developing next‑gen kinase inhibitors and anti‑HBV agents; differentiation stems from its AI‑centric discovery platform and dual focus on oncology and viral diseases.